Multicentric Neoadjuvant Pilot Phase II Study of Cetuximab Combined with Docetaxel in Operable Triple Negative Breast Cancer.
International Journal of Cancer(2015)
Key words
triple negative breast cancer,neoadjuvant chemotherapy,anti-EGFR therapy,pathological complete response,predictive biomarkers
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined